BrUOG-PROS-221 Neoadjuvant Weekly Ixabepilone for High Risk, Clinically Localized Prostate Cancer: A Phase II Study.
Phase of Trial: Phase II
Latest Information Update: 23 Mar 2017
At a glance
- Drugs Ixabepilone (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms BrUOG-Pros-221
- 10 Jun 2017 Biomarkers information updated
- 13 Feb 2017 Status changed from active, no longer recruiting to completed.
- 18 Jul 2016 Planned End Date changed from 1 Dec 2015 to 1 Dec 2016.